Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NCT03318939 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

648

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic business decision (unrelated to safety)

Conditions

NSCLC

Interventions

DRUG: Poziotinib

Sponsor

Spectrum Pharmaceuticals, Inc